tiprankstipranks
Trending News
More News >

Achilles Therapeutics Excels in Q2 with Promising Trials

Achilles Therapeutics Excels in Q2 with Promising Trials

Achilles Therapeutics (ACHL) has released an update.

Don’t Miss TipRanks’ Half-Year Sale

Achilles Therapeutics has reported a promising second quarter with a strategic collaboration with Arcturus Therapeutics to develop mRNA cancer vaccines and positive results from Phase I/IIa trials in NSCLC and melanoma. The company has a strong financial position, with $95.1 million to fund operations into 2025. The updates demonstrate the potential of Achilles’ AI-driven precision T cell therapies and the company’s continued progress in oncology.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1